{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:37Z","timestamp":1793406457506,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acinetobacter baumannii is a bacterial pathogen frequently implicated in healthcare-associated infections, with limited effective treatment options due to widespread antibiotic resistance. Sulbactam\/durlobactam is a novel \u03b2-lactam\/\u03b2-lactamase inhibitor (\u03b2L\/\u03b2LI) combination recently approved for the treatment of hospital-associated bacterial pneumonia and ventilator-associated bacterial pneumonia due to A. baumannii.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the in vitro activity of sulbactam\/durlobactam alone and in combination with 15 clinically relevant antibiotics against 22 A. baumannii clinical isolates, including 21 extensively or pandrug-resistant strains (M1\u2013M22) and one metallo-\u03b2-lactamase (MBL)-producing strain (BAA-3302). Susceptibility testing, chequerboard synergy assays, and static time-kill assays were performed to assess antimicrobial interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All 21 XDR\/PDR isolates were susceptible to sulbactam\/durlobactam (MIC\u200a&amp;lt;\u200a4\/4\u2005mg\/L), while the MBL-harbouring strain BAA-3302 showed intermediate susceptibility (MIC\u200a=\u200a8\/4\u2005mg\/L). Chequerboard assays revealed consistent synergy between sulbactam\/durlobactam and multiple \u03b2-lactams and \u03b2L\/\u03b2LI agents, including cefepime, meropenem, cefiderocol, ceftazidime\u2013avibactam, and piperacillin\u2013tazobactam, with \u226595% of strains showing synergistic effects. Selected combinations demonstrated rapid and sustained bactericidal activity against select strains in time-kill assays. Combinations with tetracyclines also showed synergy in select strains, particularly against the MBL-carrying isolate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sulbactam\/durlobactam demonstrates strong activity against highly drug-resistant A. baumannii isolates and shows enhanced potency when combined with specific \u03b2-lactam and \u03b2L\/\u03b2LI agents. Further investigation of sulbactam\/durlobactam-based combination therapy is warranted as a therapeutic strategy for the treatment of carbapenem-resistant A. baumannii infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf220","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:01:55Z","timestamp":1762520515000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of sulbactam\/durlobactam activity and synergy against highly drug-resistant\n                    <i>Acinetobacter baumannii<\/i>\n                    strains"],"prefix":"10.1093","volume":"7","author":[{"given":"Justin","family":"Halim","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University , Camden, NJ 08103 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannete","family":"Bouzo","sequence":"additional","affiliation":[{"name":"Rowan-Virtua School of Osteopathic Medicine , Stratford, NJ 08084 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-0556","authenticated-orcid":false,"given":"Valerie J","family":"Carabetta","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University , Camden, NJ 08103 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2025112104334095100_dlaf220-B1","volume-title":"StatPearls","author":"Brady","year":"2024"},{"key":"2025112104334095100_dlaf220-B2","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","article-title":"Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals","volume":"48","author":"Ibrahim","year":"2021","journal-title":"Mol Biol Rep"},{"key":"2025112104334095100_dlaf220-B3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/antibiotics13030213","article-title":"Risk factors associated with mortality in Acinetobacter baumannii infections: results of a prospective cohort study in a tertiary public hospital in Guayaquil, Ecuador","volume":"13","author":"Abarca-Coloma","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025112104334095100_dlaf220-B4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/cc5911","article-title":"Attributable mortality of Acinetobacter baumannii: no longer a controversial issue","volume":"11","author":"Falagas","year":"2007","journal-title":"Crit Care"},{"key":"2025112104334095100_dlaf220-B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025112104334095100_dlaf220-B6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1089\/mdr.2014.0234","article-title":"Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter spp. in Asia and Oceania","volume":"21","author":"Kamolvit","year":"2015","journal-title":"Microb Drug Resist"},{"key":"2025112104334095100_dlaf220-B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13756-024-01376-7","article-title":"Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis","volume":"13","author":"Bostanghadiri","year":"2024","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025112104334095100_dlaf220-B8","doi-asserted-by":"publisher","first-page":"e0101021","DOI":"10.1128\/Spectrum.01010-21","article-title":"Tigecycline heteroresistance and resistance mechanism in clinical isolates of Acinetobacter baumannii","volume":"9","author":"Jo","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2025112104334095100_dlaf220-B9","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.modpat.2023.100249","article-title":"Emerging antimicrobial resistance","volume":"36","author":"Flynn","year":"2023","journal-title":"Mod Pathol"},{"key":"2025112104334095100_dlaf220-B10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/phar.2802","article-title":"Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections","volume":"43","author":"El-Ghali","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"2025112104334095100_dlaf220-B11","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1093\/cid\/ciad095","article-title":"Durlobactam, a broad-spectrum serine \u03b2-lactamase inhibitor, restores sulbactam activity against Acinetobacter species","volume":"76","author":"Papp-Wallace","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025112104334095100_dlaf220-B12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025112104334095100_dlaf220-B13","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","volume":"2024","author":"Tamma","journal-title":"Clin Infect Dis"},{"key":"2025112104334095100_dlaf220-B14","doi-asserted-by":"publisher","first-page":"01576-17","DOI":"10.1128\/AAC.01576-17","article-title":"Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel \u03b2-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii","volume":"62","author":"McLeod","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112104334095100_dlaf220-B15","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/antibiotics11121793","article-title":"Acinetobacter baumannii resistance to sulbactam\/durlobactam: a systematic review","volume":"11","author":"Principe","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025112104334095100_dlaf220-B16","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/antibiotics10111344","article-title":"Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii","volume":"10","author":"Karakonstantis","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025112104334095100_dlaf220-B17","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1093\/jac\/dkad244","article-title":"In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales","volume":"78","author":"Fouad","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025112104334095100_dlaf220-B18","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dkaf306","article-title":"Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms","volume":"80","author":"Halim","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025112104334095100_dlaf220-B19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/microorganisms12071353","article-title":"Combinations of antibiotics effective against extensively- and pandrug-resistant Acinetobacter baumannii patient isolates","volume":"12","author":"Halim","year":"2024","journal-title":"Microorganisms"},{"key":"2025112104334095100_dlaf220-B20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","article-title":"Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth","volume":"94","author":"Hackel","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025112104334095100_dlaf220-B21","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/antibiotics11101298","article-title":"Evaluating the efficacy of eravacycline and omadacycline against extensively drug-resistant Acinetobacter baumannii patient isolates","volume":"11","author":"Deolankar","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025112104334095100_dlaf220-B22","author":"CLSI"},{"key":"2025112104334095100_dlaf220-B23","doi-asserted-by":"publisher","first-page":"e0078122","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2025112104334095100_dlaf220-B24","doi-asserted-by":"publisher","first-page":"ofad500.2135","DOI":"10.1093\/ofid\/ofad500.2135","article-title":"Activity of sulbactam-durlobactam, antibacterial combinations, and comparators against a challenge set of 66 Acinetobacter baumannii-calcoaceticus species complex isolates","volume":"10","author":"Huband","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025112104334095100_dlaf220-B25","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nat Microbiol"},{"issue":"Suppl 1","key":"2025112104334095100_dlaf220-B26","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","article-title":"Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997-2016)","volume":"6","author":"Gales","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025112104334095100_dlaf220-B27","doi-asserted-by":"publisher","first-page":"e0047922","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025112104334095100_dlaf220-B28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/clinids\/4.2.237","article-title":"Bactericidal synergism between beta-lactams and aminoglycosides: mechanism and possible therapeutic implications","volume":"4","author":"Davis","year":"1982","journal-title":"Rev Infect Dis"},{"key":"2025112104334095100_dlaf220-B29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/mmi.14594","article-title":"Inactivation of AdeABC and AdeIJK efflux pumps elicits specific nonoverlapping transcriptional and phenotypic responses in Acinetobacter baumannii","volume":"114","author":"Leus","year":"2020","journal-title":"Mol Microbiol"},{"key":"2025112104334095100_dlaf220-B30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s43856-024-00591-y","article-title":"Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria","volume":"4","author":"Dulanto Chiang","year":"2024","journal-title":"Commun Med (Lond)"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/6\/dlaf220\/65387826\/dlaf220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/6\/dlaf220\/65387826\/dlaf220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:33:49Z","timestamp":1763717629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf220\/8327561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf220","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"dlaf220"}}